Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Synthetic biology in 2026: a crash course

    Synthetic biology treats living systems as engineerable: DNA is written to order, genetic circuits are designed and measured in bulk, and engineered organisms brew defined products.[1][2][3] As of October 2026 genome writing has produced finished artefacts, circuit design has become a data problem, and the binding constraints are industrial capacity and unfinished screening policy.[4][5][6][7]

    Editor reviewedUpdated Synthetic biologyLife sciencesScience

    Why the field matters

    Synthetic biology is the attempt to engineer living systems the way we engineer machines: specify what you want, write the DNA, put it in a cell or a tube, measure what happens, and iterate. Two things make that practical now. DNA can be bought cheaply in bulk, with one supplier shipping about 369,000 genes in a single quarter of 2026.[1] And engineered organisms already make real products, such as an egg protein brewed by a fungus that the US Food and Drug Administration raised no questions about in September 2025.[8][3]

    The payoff would be making medicines, food ingredients, chemicals and materials by growing them rather than extracting or synthesising them chemically. The obstacle is rarely imagination; it is reliability at scale and the industrial plant needed to get there.[6]

    The field’s claim is that biological function can be specified, composed and manufactured. Each word hides a bottleneck. Specification is limited by how little of a genome’s function is predictable: even the minimal cell JCVI-syn3.0, at about 473 genes, retains unannotated genes required for normal growth.[9][10] Composition is limited by context dependence, which is why 2026’s advance was measuring huge design libraries rather than improving a model of one circuit.[2][11] Manufacturing is limited by tankage and cost of goods, not by strain availability.[6][12]

    National-security framing now shapes funding: a congressionally created commission recommended at least $15 billion of US investment in April 2025, and defence money is building shared fermentation plants.[13][14][15]

    The map of the field

    Five sub-areas cover most of the work.

    Writing DNA. Synthesis and assembly turn sequence into molecule. Array-based chemistry dominates volume; enzymatic synthesis competes on construct length, with clonal products advertised up to 50 kilobases.[16][17] See how DNA synthesis works.

    Genome writing. Whole chromosomes and genomes are designed, built in fragments and debugged: Sc2.0 completed its chromosome set in January 2025, and Syn57 recoded a four-megabase bacterial genome with more than 101,000 codon changes.[4][5]

    Genetic circuits. DNA that makes cells sense and decide. The 2026 method shift was high-throughput mapping plus machine learning.[2][18]

    Cell-free and minimal systems. Cell-free extracts express genes without a host at about 4 milligrams per millilitre, and minimal cells serve as simplified chassis used by more than 90 groups.[19][20]

    Biomanufacturing. Growing engineered organisms at volume and purifying the product, including precision fermentation of specific proteins.[3] See how biomanufacturing works.

    Running across all five is governance of the synthesis supply chain: order screening, which the United States ties to federal research funding.[21]

    Key ideas worth holding onto

    First, long DNA is hard, so big designs are built from small verified pieces and then fixed where they fail; the yeast project needed a dedicated CRISPR-based debugging protocol.[22] Second, biological parts are not like electronic components: the same promoter behaves differently in a different design, so engineers test many versions.[11] Third, making a gram in a flask and a tonne in a tank are different problems, and the second one needs expensive equipment.[23]

    Three quantitative anchors are useful. Length: commercial clonal constructs top out around 50 kb, with conventional routes generally below about 10 kb, so megabase projects remain fragment-and-recombine exercises.[16][17][5] Throughput: design-space mapping now reaches hundreds of thousands to millions of variants per experiment, which changes what counts as a design method.[2] Scale: demonstration fermentation means 25,000-litre vessels, with pilot steps at up to 4,000 litres in Hayward and 5,000 and 10,000 litres in Iowa.[23][24][25]

    A fourth anchor is negative: minimal genomes are not fully explained, so bottom-up prediction of cell behaviour remains incomplete.[10]

    Who the main players are

    Suppliers of inputs are the healthiest businesses. Twist Bioscience reported record revenue of $118.4 million for the quarter to June 2026 and raised full-year guidance to about $456 million to $457 million.[26][27] Enzymatic specialists compete on length and on-site synthesis, and public funders back the approach: ARPA-H awarded up to $26 million to DNA Script and GE HealthCare in August 2026.[28][29]

    Platform service companies have had a harder time. Ginkgo Bioworks reported $20.2 million of revenue and a $46.7 million net loss for the quarter to June 2026, after cutting more than half its workforce and divesting biosecurity.[30][31][32]

    Public institutions are increasingly the demand side and the landlord. BioMADE, a Manufacturing USA institute, is building shared plants with Department of Defense money, and government and defence customers supplied 45% of Ginkgo’s second-quarter 2026 revenue.[33][15][34] Academic consortia hold the genome-writing frontier, from Sc2.0 to recoded bacteria.[35][36]

    Where the frontier is, October 2026

    Four live edges. Design methodology: whether models trained on massive measured libraries transfer from human cell lines to industrial hosts.[37][18] Genome writing: consolidating and characterising fully synthetic eukaryotic genomes, and exploiting freed codons in recoded bacteria for non-canonical amino acids and virus resistance.[35][36] Manufacturing: whether the new pilot and demonstration plants fill, with Hayward aimed at opening to customers in early 2026 and the Iowa date moving between 2027 and early 2028.[24][38] Governance: the replacement US screening framework ordered in May 2025 that had not been published as of October 2026, against documented gaps in definitions, capacity and provider consistency.[7][39][40]

    Two October and August 2026 results show where the design thread has reached. Nature Biotechnology published Shotgun Genetic Engineering on 6 October 2026, which screens millions of mammalian pathway combinations by delivering many barcoded small constructs instead of one large one; the pathways that worked still required 23 to 52 kilobases of synthetic DNA per cell.[41][42][43] And in August 2026 Twist Bioscience disclosed in an SEC filing that anthropic had used it as one of the independent evaluators for AI-designed protein binders against 15 targets,[44] with the developer reporting binders against 14 of them at hit rates of 22.6 to 35.1 percent.[45] Both figures come from the organisations that produced them. Disclosure: Anthropic also provides the model used to draft pages on this site.

    How to use this course

    Read the three fundamentals first, then the technology and company pages, then the two debates, and keep the tracker for new milestones. The pages are listed in order in this page’s course list, ending with the frontier tracker.[2]

    Questions readers ask

    What is synthetic biology?

    Engineering biology deliberately: writing DNA to order, designing genetic circuits that make cells respond in defined ways, and using engineered organisms or cell-free reactions to make products.[46][3][2]

    Can scientists write a whole genome?

    Yes, in pieces and with debugging. The synthetic yeast project completed its chromosome set with the 903-kilobase synXVI in January 2025, and a four-megabase recoded Escherichia coli genome was published in 2025.[4][5]

    What changed in 2026?

    Circuit design became a measurement problem. A January 2026 Nature paper measured hundreds of thousands to millions of designs at once and trained models that predicted untested variants.[2][18]

    What is holding commercial biomanufacturing back?

    Capacity and economics. The United States is reported to lack pilot- and demonstration-scale fermentation equipment, while the best-known cell engineering company cut more than half its workforce.[6][31]

    How is DNA synthesis governed?

    Chiefly through procurement. The 2024 US framework ties federal research funding to buying from compliant providers, including benchtop device makers, and a replacement ordered in May 2025 has not been published.[21][7]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      Twist Bioscience shipped about 369,000 synthetic genes in the third quarter of fiscal 2026, against about 237,000 in the same quarter of fiscal 2025. confirmedas of 2026-08-05

    2. [2]

      On 14 January 2026 a Rice University-led team reported CLASSIC in Nature, a method that combines long-read and short-read sequencing to measure hundreds of thousands to millions of genetic circuit designs in one experiment. confirmedas of 2026-01-14

    3. [3]

      Onego Bio's Bioalbumen is ovalbumin with the same amino acid sequence as chicken egg white protein, made by precision fermentation in the filamentous fungus Trichoderma reesei. confirmedas of 2025-09-24

    4. [4]

      The final synthetic chromosome of the Sc2.0 project, the 903-kilobase synXVI, was reported in Nature Communications on 20 January 2025. confirmedas of 2025-01-22

    5. [5]

      Syn57 is an Escherichia coli strain whose 4-megabase genome was built by total synthesis with more than 101,000 codon changes, giving it a 57-codon genetic code; the work was published in Science in 2025. confirmedas of 2025-08-01

    6. [6]

      The United States is reported to be severely short of pilot- and demonstration-scale equipment for precision fermentation, which is the stated reason for federal investment in bioindustrial pilot plants. reportedas of 2026-05-11

    7. [7]

      Under the executive order "Improving the Safety and Security of Biological Research" of 5 May 2025, federal agencies are to revise or replace the 2024 framework, and as of October 2026 the responsible US government page says it will be updated once the revised framework is available. confirmedas of 2026-10-10

    8. [8]

      On 24 September 2025 Onego Bio said the US Food and Drug Administration had issued a "no questions" letter on the GRAS status of its Bioalbumen egg protein, filed as GRAS Notice GRN 1249. confirmedas of 2025-09-24

    9. [9]

      JCVI-syn3.0, derived from Mycoplasma mycoides subspecies capri, carries about 473 genes and is described as the simplest bacterium capable of autonomous growth in axenic culture. confirmedas of 2025-06-02

    10. [10]

      Some minimal-cell genes remain poorly understood, including an unannotated transaldolase that the cell needs to reach a two-hour doubling time. confirmedas of 2025-06-02

    11. [11]

      The CLASSIC study found that many different part combinations can produce the same circuit function and that medium-strength components often outperform the strongest or weakest ones. reportedas of 2026-01-14

    12. [12]

      BioMADE says the shortage of pilot- to demonstration-scale capacity forces American companies to use facilities overseas, taking innovation with them and risking loss of intellectual property. confirmedas of 2025-04-29

    13. [13]

      The National Security Commission on Emerging Biotechnology, a bipartisan body created by the fiscal 2022 National Defense Authorization Act, delivered its final report "Charting the Future of Biotechnology" to Congress in April 2025 with 49 recommendations. confirmedas of 2025-04-30

    14. [14]

      The commission's headline recommendation is at least $15 billion of US government investment to grow biotechnology innovation and biomanufacturing. confirmedas of 2025-04-30

    15. [15]

      The US Department of Defense gave BioMADE about $87 million at its inception and directed a further $450 million to it in 2023. reportedas of 2026-05-11

    16. [16]

      Ansa Biotechnologies announced commercial availability of clonal DNA constructs up to 50 kilobases made on its enzymatic DNA synthesis platform, roughly 100 times longer than its first product. reportedas of 2025-10-01

    17. [17]

      Ansa Biotechnologies says industry-standard DNA synthesis approaches generally cannot produce constructs longer than about 10 kilobases. reportedas of 2025-10-01

    18. [18]

      Machine-learning models trained on CLASSIC measurements predicted the behaviour of untested genetic circuit variants, and all 40 designs the team checked by hand matched the prediction. reportedas of 2026-01-14

    19. [19]

      The all-E. coli TXTL toolbox 3.0 reported protein synthesis of 4 milligrams per millilitre in batch reactions and more than 8 milligrams per millilitre inside synthetic cell compartments. confirmedas of 2021-08-04

    20. [20]

      More than 90 research groups have used or studied the JCVI minimal cell and related strains since the 2016 publication. confirmedas of 2025-06-02

    21. [21]

      The 2024 framework makes it a condition of US federal life-sciences research funding that synthetic nucleic acids, and benchtop devices that can make them, are bought only from providers and manufacturers that comply with the framework. confirmedas of 2026-10-10

    22. [22]

      The Sc2.0 team used a CRISPR-based debugging protocol, D-BUGS, to locate and correct design errors in synthetic chromosomes that impaired yeast growth. confirmedas of 2025-01-22

    23. [23]

      On 29 April 2025 BioMADE finalised a $132 million investment, funded by the US Department of Defense and Minnesota's economic development department, in a 122,000-square-foot demonstration-scale biomanufacturing facility in Maple Grove, Minnesota with two 25,000-litre industrial fermenters. confirmedas of 2025-04-29

    24. [24]

      BioMADE's California pilot plant in Hayward is a nearly 25,000-square-foot multi-user facility with aerated stirred tanks of up to 4,000 litres, in a project worth at least $80 million funded by the US Department of Defense; BioMADE said in April 2025 that it aimed to open it to customers in early 2026. confirmedas of 2025-04-30

    25. [25]

      BioMADE's Iowa pilot plant, built near Ames with Iowa State University, is a 15,000-square-foot multi-user site with 5,000 and 10,000-litre industrial fermenters, in a $40 million project to which BioMADE committed at least $20 million, matched by up to $10 million from the university and $10 million from a state infrastructure programme. confirmedas of 2025-11-14

    26. [26]

      Twist Bioscience reported record revenue of $118.4 million for the third quarter of fiscal 2026, more than 23% above the $96.1 million of the same quarter a year earlier. confirmedas of 2026-08-05

    27. [27]

      Twist Bioscience raised its fiscal 2026 revenue expectation to $456 million to $457 million, about 21% year-on-year growth. confirmedas of 2026-08-05

    28. [28]

      On 4 August 2026 DNA Script said it and GE HealthCare had been awarded up to $26 million by ARPA-H to advance cell-free DNA bioproduction under the FLASH programme. confirmedas of 2026-08-04

    29. [29]

      DNA Script's SYNTAX system is a benchtop enzymatic DNA printer that produces custom oligonucleotides on site in hours rather than days. reportedas of 2026-10-10

    30. [30]

      Ginkgo Bioworks reported total revenue of $20.2 million and a net loss of $46.7 million for the quarter ended 30 June 2026. confirmedas of 2026-06-30

    31. [31]

      Ginkgo Bioworks cut more than half its workforce in a restructuring that was substantially concluded by 31 December 2025, with facility consolidation continuing through 2026. confirmedas of 2026-06-30

    32. [32]

      After divesting its biosecurity business in April 2026, Ginkgo Bioworks reports as a single segment covering biological research services and tools. confirmedas of 2026-06-30

    33. [33]

      BioMADE is a Manufacturing USA institute for bioindustrial manufacturing that works to build national infrastructure for taking biotechnology from laboratory scale to commercial production. confirmedas of 2025-04-29

    34. [34]

      Government and defence customers accounted for 45% of Ginkgo Bioworks' revenue in the second quarter of 2026 and 41% in the first half, its largest customer group. confirmedas of 2026-06-30

    35. [35]

      Sc2.0 is an international project to build the first synthetic eukaryotic genome, a redesigned version of the Saccharomyces cerevisiae genome plus a new-to-nature tRNA neochromosome. confirmedas of 2025-01-22

    36. [36]

      The Syn57 team gives two intended uses for freed codons: incorporating non-canonical amino acids to make new polymers and macrocycles, and making production strains resistant to viral infection. confirmedas of 2025-08-01

    37. [37]

      The CLASSIC libraries were built as genetic circuits and inserted into human embryonic kidney cells for measurement. confirmedas of 2026-01-14

    38. [38]

      BioMADE's stated opening date for the Iowa pilot plant has moved. An August 2025 release said the site was set to open in early 2028, while the November 2025 groundbreaking release said it was scheduled to open in 2027. disputedas of 2025-11-14

    39. [39]

      A 2025 peer-reviewed analysis identified three obstacles to effective sequence-level governance: ambiguous definitions of sequences of concern, fragmented regulatory triggers, and underdeveloped institutional capacity. confirmedas of 2025-10-28

    40. [40]

      The analysis cites interview research finding substantial variation between synthesis providers in screening sensitivity, treatment of short oligonucleotides, and monitoring and evaluation. confirmedas of 2025-10-28

    41. [41]

      Nature Biotechnology published "Highly multiplexed mammalian metabolic engineering with a shotgun approach" on 6 October 2026. confirmedas of 2026-10-06

    42. [42]

      Shotgun Genetic Engineering delivers many barcoded small DNA constructs into mammalian cells rather than one large construct, so each cell carries a different synthetic pathway and functional combinations are identified by sequencing barcodes from cells with the wanted phenotype. confirmedas of 2025-07-08

    43. [43]

      The shotgun engineering authors screened millions of pathway combinations in CHO and Jurkat cells, reaching near-wild-type growth in valine-free medium and isoleucine prototrophy in CHO cells, with successful solutions requiring 23 to 52 kilobases of synthetic DNA. confirmedas of 2025-07-08

    44. [44]

      Twist Bioscience disclosed in an 18 August 2026 SEC filing that Anthropic had chosen it as one of the independent evaluators to produce at scale and test the binding of proteins designed by Anthropic's models in a campaign against 15 targets. confirmedas of 2026-08-18

    45. [45]

      Anthropic reported that its models designed binders against 14 of 15 protein targets, with overall hit rates of 26.7 percent and 22.6 percent in a multi-target setting and 35.1 percent when designing against each target separately, compared with the 10 to 15 percent it says is typical in protein design campaigns today. reportedas of 2026-08-18

    46. [46]

      Cell-free transcription-translation (TXTL) systems express genes in a tube using extracted cellular machinery, and are used to test genetic regulatory elements and circuits without living cells. confirmedas of 2021-08-04

    Revision history (2)
    1. Page created.
    2. Refresh: re-sourced the pilot-plant scale ladder to BioMADE's releases, and added October 2026 shotgun pathway engineering and the August 2026 AI-designed protein validation to the frontier section.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Synthetic biology in 2026: a crash course." ContentLora, updated Oct 10, 2026. https://contentlora.com/explain/synthetic-biology

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents